• 1. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400
• 2. Ester-mediated peptide formation promoted by deep eutectic solvents: a facile pathway to proto-peptides?
  Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952
• 3. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 4. Enabling non-flammable Li-metal batteries via electrolyte functionalization and interface engineering?
  Jing Yu,Yu-Qi Lyu,Jiapeng Liu,Mohammed B. Effat,Junxiong Wu J. Mater. Chem. A, 2019,7, 17995-18002
• 5. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Triterpene glycosides
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Terpene glycosides Triterpene glycosides
• Triterpenoids

Recent Advances in Soyasaponin Aa (117230-33-8) Research: Implications for Chemical Biology and Medicine

Soyasaponin Aa (CAS: 117230-33-8), a triterpenoid glycoside derived from soybeans, has garnered significant attention in recent years due to its diverse pharmacological properties. This research brief synthesizes the latest findings on Soyasaponin Aa, focusing on its chemical structure, biological activities, and potential therapeutic applications. The compound's unique structure, characterized by a oleanane-type aglycone and sugar moieties, underpins its multifaceted interactions with biological systems.

Recent studies have elucidated the molecular mechanisms underlying Soyasaponin Aa's anti-inflammatory and antioxidant effects. A 2023 study published in the Journal of Natural Products demonstrated that Soyasaponin Aa inhibits NF-κB signaling pathway in macrophages, reducing pro-inflammatory cytokine production by up to 60% at concentrations of 10-50 μM. This finding suggests potential applications in chronic inflammatory disorders. Concurrently, research in Free Radical Biology and Medicine revealed the compound's potent ROS-scavenging capacity, with an EC50 of 8.2 μM against superoxide anions, positioning it as a promising candidate for oxidative stress-related conditions.

The compound's anticancer properties have been extensively investigated in the past two years. A breakthrough study in Cancer Letters (2024) showed that Soyasaponin Aa induces apoptosis in colorectal cancer cells through upregulation of Bax/Bcl-2 ratio and caspase-3 activation, with IC50 values ranging from 15-25 μM across different cell lines. Notably, the research highlighted the compound's selective cytotoxicity, sparing normal intestinal epithelial cells at therapeutic concentrations. These findings were corroborated by in vivo experiments showing 40-50% tumor growth inhibition in xenograft models.

Pharmacokinetic studies of Soyasaponin Aa have advanced significantly, addressing previous challenges with bioavailability. A 2024 paper in Drug Metabolism and Disposition reported that novel nanoemulsion formulations improved oral bioavailability from 2.3% to 18.7% in rat models. This technological advancement, coupled with the identification of major metabolites through LC-MS/MS analysis, provides crucial insights for future formulation development and clinical translation.

Emerging research has explored Soyasaponin Aa's potential in metabolic disorders. A recent clinical trial (Phase IIa) published in Diabetes Care demonstrated that daily supplementation with 100 mg Soyasaponin Aa for 12 weeks significantly improved insulin sensitivity (HOMA-IR reduction of 22.4%) in prediabetic patients. The study also reported favorable safety profiles, with adverse event rates comparable to placebo. These findings open new avenues for developing Soyasaponin Aa-based nutraceuticals for metabolic syndrome management.

In conclusion, the growing body of research on Soyasaponin Aa (117230-33-8) underscores its therapeutic potential across multiple disease areas. While challenges remain in formulation optimization and clinical validation, the compound's multimodal mechanisms of action and favorable safety profile position it as a promising candidate for further development. Future research directions should focus on structure-activity relationship studies to enhance potency and the development of targeted delivery systems to maximize therapeutic efficacy.

• 117230-35-0(b-D-Glucopyranosiduronic acid, (3b,4b,21b,22b)-21,23-dihydroxy-22-[[3-O-(2,3,4-tri-O-acetyl-b-D-xylopyranosyl)-a-L-arabinopyranosyl]oxy]olean-12-en-3-yl2-O-a-L-arabinopyranosyl-)
• 118194-13-1(Soyasaponin Ab)
• 184840-43-5(b-D-Glucopyranosiduronic acid, (3b,4a,20a,21b,22b)-22,23,29-trihydroxy-21-[(2,3,4-tri-O-acetyl-6-deoxy-a-L-mannopyranosyl)oxy]olean-12-en-3-yl2-O-b-D-glucopyranosyl- (9CI))
• 117230-32-7(Acetylsoyasaponin A2)
• 117230-34-9(b-D-Glucopyranosiduronic acid, (3b,4b,21b,22b)-21,23-dihydroxy-22-[[3-O-(2,3,4-tri-O-acetyl-b-D-xylopyranosyl)-a-L-arabinopyranosyl]oxy]olean-12-en-3-yl2-O-b-D-galactopyranosyl-)
• 117210-16-9(β-D-Glucopyranosiduronic acid, (3β,4β,21β,22β)-21,23-dihydroxy-22-[[3-O-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)-α-L-arabinopyranosyl]oxy]olean-12-en-3-yl 2-O-α-L-arabinopyranosyl-)
• 168109-50-0(b-D-Glucopyranosiduronic acid, (3b,4a,20a,21b,22b)-22,23,29-trihydroxy-21-[(2,3,4-tri-O-acetyl-6-deoxy-a-L-mannopyranosyl)oxy]olean-12-en-3-yl(9CI))
• 152505-06-1(b-D-Glucopyranosiduronic acid, (3b,4b,21b,22b)-21,23-dihydroxy-22-[[3-O-(2,3,4-tri-O-acetyl-b-D-xylopyranosyl)-a-L-arabinopyranosyl]oxy]olean-12-en-3-ylO-b-D-glucopyranosyl-(1®2)-O-a-L-arabinopyranosyl-(1®2)- (9CI))
• 147934-05-2(Gymnemic acid X)
• 168109-51-1((2S,3S,4S,5R,6R)-6-[[(3S,4R,4Ar,6aR,6bS,8aR,9S,10R,11R,12aS,14aR,14bR)-9-hydroxy-4,11-bis(hydroxymethyl)-4,6a,6b,8a,11,14b-hexamethyl-10-[(2S,3R,4R,5S,6S)-3,4,5-triacetyloxy-6-methyloxan-2-yl]oxy-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3,4-dihydroxy-5-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxane-2-carboxylic acid)